Literature DB >> 15295007

Opioid-like actions of neuropeptide Y in rat substantia gelatinosa: Y1 suppression of inhibition and Y2 suppression of excitation.

Timothy D Moran1, William F Colmers, Peter A Smith.   

Abstract

Neuropathic pain that results from injury to the peripheral or CNS responds poorly to opioid analgesics. Y1 and Y2 receptors for neuropeptide Y (NPY) may, however, serve as targets for analgesics that retain their effectiveness in neuropathic pain states. In substantia gelatinosa neurons in spinal cord slices from adult rats, we find that NPY acts via presynaptic Y2 receptors to attenuate excitatory postsynaptic currents (EPSCs) and predominantly on presynaptic Y1 receptors to attenuate glycinergic and GABAergic inhibitory postsynaptic currents (IPSCs). Because NPY attenuates the frequency of TTX-resistant miniature EPSCs and IPSCs, perturbation of the neurotransmitter release process contributes to its actions at both excitatory and inhibitory synapses. These effects, which are reminiscent of those produced by analgesic opioids, provide a cellular basis for previously documented spinal analgesic actions mediated via Y1 and Y2 receptors in neuropathic pain paradigms. They also underline the importance of suppression of inhibition in spinal analgesic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15295007     DOI: 10.1152/jn.00096.2004

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  14 in total

1.  Neuropeptide Y Y1 receptor effects on pulpal nociceptors.

Authors:  J L Gibbs; K M Hargreaves
Journal:  J Dent Res       Date:  2008-10       Impact factor: 6.116

2.  Activation of NPY type 5 receptors induces a long-lasting increase in spontaneous GABA release from cerebellar inhibitory interneurons.

Authors:  C J Dubois; P Ramamoorthy; M D Whim; S J Liu
Journal:  J Neurophysiol       Date:  2011-12-21       Impact factor: 2.714

Review 3.  Neuropeptides and their receptors: innovative science providing novel therapeutic targets.

Authors:  Susan D Brain; Helen M Cox
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Neuron type-specific effects of brain-derived neurotrophic factor in rat superficial dorsal horn and their relevance to 'central sensitization'.

Authors:  Van B Lu; Klaus Ballanyi; William F Colmers; Peter A Smith
Journal:  J Physiol       Date:  2007-08-30       Impact factor: 5.182

5.  Brain-derived neurotrophic factor drives the changes in excitatory synaptic transmission in the rat superficial dorsal horn that follow sciatic nerve injury.

Authors:  Van B Lu; James E Biggs; Martin J Stebbing; Sridhar Balasubramanyan; Kathryn G Todd; Aaron Y Lai; William F Colmers; David Dawbarn; Klaus Ballanyi; Peter A Smith
Journal:  J Physiol       Date:  2009-01-05       Impact factor: 5.182

6.  Endogenous neuropeptide Y depresses the afferent signaling of gastric acid challenge to the mouse brainstem via neuropeptide Y type Y2 and Y4 receptors.

Authors:  T Wultsch; E Painsipp; C K Thoeringer; H Herzog; G Sperk; P Holzer
Journal:  Neuroscience       Date:  2005-10-10       Impact factor: 3.590

Review 7.  Therapeutic potential of neuropeptide Y (NPY) receptor ligands.

Authors:  Shaun P Brothers; Claes Wahlestedt
Journal:  EMBO Mol Med       Date:  2010-11       Impact factor: 12.137

8.  Quantitative study of NPY-expressing GABAergic neurons and axons in rat spinal dorsal horn.

Authors:  Erika Polgár; Thomas C P Sardella; Masahiko Watanabe; Andrew J Todd
Journal:  J Comp Neurol       Date:  2011-04-15       Impact factor: 3.215

9.  Fast A-type currents shape a rapidly adapting form of delayed short latency firing of excitatory superficial dorsal horn neurons that express the neuropeptide Y Y1 receptor.

Authors:  Ghanshyam P Sinha; Pranav Prasoon; Bret N Smith; Bradley K Taylor
Journal:  J Physiol       Date:  2021-04-18       Impact factor: 6.228

Review 10.  Targeting spinal neuropeptide Y1 receptor-expressing interneurons to alleviate chronic pain and itch.

Authors:  Tyler S Nelson; Bradley K Taylor
Journal:  Prog Neurobiol       Date:  2020-08-07       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.